Recent studies have established that the circadian clock influences onset, progression and 37 therapeutic outcomes in a number of diseases including heart disease and cancer. There are, however, no 38 tools to monitor the functional state of the circadian clock and its downstream targets in humans. We 39 provide such a tool and demonstrate its clinical relevance by an application to breast cancer where we 40 find a strong link between overall survival and our measure of clock dysfunction. We use a machine-41 learning approach and construct an algorithm called TimeTeller which uses the multi-dimensional state of 42 the genes in a transcriptomics analysis of a single biological sample to assess the level of circadian clock 43 dysfunction. We demonstrate how this can distinguish differences between healthy and diseased tissue 44 and demonstrate that the clock dysfunction metric is a potentially new prognostic and predictive breast 45 cancer biomarker that is independent of the main established prognostic factors. 46
Introduction
The cell-endogenous circadian clock regulates tissue-specific gene expression in cells that drives 48 rhythmic daily variation in metabolic, endocrine, and behavioural functions. Indeed, around half of all 49 mammalian genes are expressed with a 24-hour rhythm (1, 2) . Moreover, recent studies demonstrated that 50 the circadian clock influences therapeutic outcomes in a number of diseases including heart disease and 51 cancer (3) (4) (5) (6) (7) (8) (9) , and that disruption of the normal circadian rhythm and sleep (e.g. through shift work) is 52 associated with higher risk of obesity, hypertension, diabetes, CHD, stroke and cancer (10) (11) (12) (13) . 53 A principal aim of circadian medicine (14, 15) is to develop techniques and methods to integrate 54 the relevance of biological time into clinical practice. However, although circadian disruption is known to 55 affect multiple organs, it is difficult to monitor the functional state of the circadian clock and its 56 downstream targets in humans. Consequently, there is a critical need for tools to do this that are practical 57 in a clinical context. Our focus is on the development of such a technique, and here we will illustrate its 58 utility to predict breast cancer survival. We present a machine-learning approach to measuring circadian 59 clock functionality from the expression levels of 10-15 key genes in a single tissue sample. Our algorithm 60 is applied to breast cancer where previous studies have highlighted the relevance of circadian clocks for 61 carcinogenesis and treatment effects (16) (17) (18) (19) but where no simple method would currently allow its 62 measurement in daily oncology practice. We find a strong link between overall survival and our measure 63 of clock dysfunction. 64
There are now several algorithms which aim to estimate the time at which a transcriptomic dataset 65 was collected using the expression levels of the core clock genes (14, (20) (21) (22) (23) (24) (25) . While these have hinted at 66 the idea of using such a time-telling approach to measure circadian clock functionality (23) they are not 67 purposely constructed to do this, but rather to predict internal timing of functional host circadian systems 68 (Note S6). Moreover, for practical use, it is highly desirable to be able to do this using just a single 69 clinical sample, and these algorithms do not attempt this. We therefore developed a new algorithm called 70 TimeTeller to estimate clock functionality from a single sample. 71
While in the cells of most healthy tissues the cell cycle is gated or phase-locked by the circadian 72 clock (26, 27) , cancer cells often escape this control and display altered molecular clocks (28) (29) (30) . 73
Dysregulation of clock genes promotes tumorigenesis (22) through mechanisms involving the cell cycle 74 (31, 32) , DNA damage (33), and metabolism (34). Moreover, the circadian clock rhythmically controls 75 many molecular pathways which are responsible for large time-of-day dependent changes in drug toxicity 76 and efficacy (3, 4, 35) . It is therefore of interest to determine whether the functionality of the clock in 77 tumour tissue is a prognostic factor for treatment response and survival. 78 We demonstrate that TimeTeller can characterise differences in the distribution of the dysfunction 79 metric between healthy and diseased tissue and between different disease strata, and that the dysfunction 80 metric can be used as a prognostic factor to identify differences in outcome. In particular, we show that in 81 a large cohort of patients with non-metastatic breast cancer the resulting TimeTeller dysfunction metric is 82 a prognostic factor for survival and provide evidence that it is independent of other known factors. In this 83 cohort, 82% of the patients with good clock function (i.e. for which the dysfunction metric is below a 84 natural threshold) survive past ten years while only 62% of the others survive as long. 85
Our approach directly assesses the systemic functionality of a key regulatory system, the circadian 86 clock, from one sample. A key aspect is that we directly assess the multi-dimensional state of the clock 87 genes and study the coordinated behaviour of all the genes together rather than focus on each gene 88 separately. In this way, we can measure the functionality of the clock system as a whole much more 89 effectively. 90
Results 91
The mouse and human versions of TimeTeller are trained on two different datasets. The mouse 92 dataset, from Zhang et al. ((1) , Note S1) consists of the transcriptomes of 12 mouse tissues measured 93 every 2 hours over 48 hours while the human training data set from Bjarnason et al. ((36) , Note S1) 94 comes from punch biopsies of oral mucosa taken every four hours over 24 hours from five females and 95 five males. This human dataset was chosen because a key initial aim was to develop TimeTeller in order 96 to analyse clock function in the tumour biopsies from the REMAGUS trial (37) and our analysis 97 suggested that it was important to match the microarray technologies ( Fig. S2 ) which in this case was 98 Affymetrix U133 2.0. The procedure for using these datasets to successfully produce TimeTeller's 99 probability model is explained in the Materials and Methods section. 100
Rhythmicity and synchronicity analysis was used to determine the panel of genes for TimeTeller 101 (Materials and Methods, SI Fig. S1 , Table S2 ). This analysis is essential to ensure the choice of a panel of 102 genes with good circadian rhythmicity combined with minimal variation across tissues and datasets. It 103 typically produces a panel of between 10 and 16 gene probes and, for the human dataset, the genes 104 selected were all core clock genes or key clock-controlled genes, including ARNTL (BMAL1), NPAS2, 105 PER1, PER2, PER3, NR1D1, NR1D2 (REV-ERBα), CIART (CHRONO), TEF and DBP. 106 TimeTeller works on the combined expression level of these genes and calculates a likelihood 107 curve LX(t) which for healthy tissue should express the probability that the expression profile X was 108 measured at time t. If this time is not known, then it is natural to estimate it as the time T at which LX(t) is 109 maximal i.e. at the maximum likelihood estimate (MLE) (Materials and Methods). Then we can 110 characterise precision using ideas from statistics and information theory to obtain a quantity, which we 111 denote by Θ, that characterises the imprecision of the estimate T (Materials and Methods). We call Θ the 112 clock dysfunction metric based on the hypothesis that precise timekeeping implies good functionality. 113
We have tested this clock dysfunction metric using both simulated and real data. Simulated data 114 were obtained by developing a stochastic version of a relatively detailed published model of the 115 mammalian circadian clock (38) and stochastically simulating this (Note S5). This data was used to 116 design the algorithm and to test the effectiveness of TimeTeller, for example, to determine the advantage 117 of local approaches over a global one ( Fig. S3 , Tables S4 & S5) , and to analyse TimeTeller's 118 effectiveness in detecting the efficiency of partial knockdowns of various efficiencies of the central clock 119 gene BMAL1 (ARNTL). We found ( Fig S7) that the efficiency of the knockdown was effectively 120 recapitulated by an increase in Θ. We then applied TimeTeller to a number of mouse and human datasets. 121
In healthy tissue TimeTeller accurately assesses time and identifies variation in chronotype. 122
To assess the accuracy of TimeTeller in estimating the time T of a sample and to evaluate the 123 likelihood curves LX(t), we firstly tested it on the training datasets using a leave-one-out approach. For the 124 Zhang et al. mouse data, we removed the tissues one at a time, constructed the probability model for 125
TimeTeller using the expression profiles from the other tissues and then used TimeTeller to estimate the 126 times of the transcriptomes for the removed tissue. For the human Bjarnason et al. data we carried out a 127 similar leave-one-out approach but where an individual rather than a tissue was left out. 128 
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The results are shown in Fig. 1 and the accuracy of the estimations is apparent (Fig. 1A,B ). For the 152 Bjarnason et al. human data the mean absolute error is 1.32h (Table S3 ) but analysis shows that much of 153 this comes from chronotype variation. For example, Male15 and Female18 in Fig. 1B have consistent, yet 154 opposite, phase shifts in their estimated times. To further understand this, we plotted the error in the 155 TimeTeller estimate against the phase of each of the genes in the TimeTeller panel ( Fig. 1D & Fig. S5 ), 156 using COSINOR (40) to measure gene phase. The part of this error at a given time not due to chronotype variation is indicated by the distance of the plotted points from the line where is the 158 expected phase of the gene at that time, shown by the horizontal black line. We see that the points are 159 typically very close to and that the disposition of the points is similar across genes ( Fig. 1D & 160 Fig. S5 ). We are therefore able to identify coherent phase variation in the clock genes for each individual. 161
For the mice, no coherent phase shift was found for any of the tissues as would be expected from 162 their genetic homogeneity and the mixing of material from multiple mice. Moreover, in this case the use 163 of the full 48-hour space allows us to observe that TimeTeller's transcriptomic time signature at CTt is 164 essentially the same as at CT(t+24). This means that there is no significant change to the circadian clock 165 gene shape after the mice have been in the dark for an extra 24 hours. 166
Healthy tissue clocks in mice are characterised by a clear upper threshold. 167
The range of Θ values resulting from applying TimeTeller to the mouse training dataset using a 168 leave-one-out approach as above are shown in the histogram in Fig. 2A . The upper bound to this range 169 helps us to define what Θ values represent a functioning circadian clock. The majority of the data has Θ < 170 0.1, but the distribution has a tail up to approximately Θ = 0.2. We therefore define good clock function 171 (GCF) for mouse samples as those having
. We refer to thresholds chosen in this way as a 172 priori as they have the advantage of being chosen naturally without the potential issues associated with 173 tuning and optimisation, for example to maximise statistical significance. 41), Note S1.2), which uses the same microarrays and obtained very 195 good agreement (Fig. 2B ). The mean absolute error for time estimation is less than one hour. The Θ 196 values range between 0.02 and 0.11 with one value at Θ = 0.17 ( Fig. 2B ). Thus, all values fall within the 197 GCF criterion defined in the previous section. 198
TimeTeller can identify perturbed but functioning clocks. 199
The gene REV-ERBα is regarded as the main controller of the ZT18-24 phase of the mammalian 200 circadian clock (42) and, interestingly, activation of clock REV-ERBα can be a therapeutic approach for 201 several types of cancer (43) and life-threatening cholangitis (44). Thus, knocking REV-ERBα out leaves a 202 functional but perturbed clock when compared to wild-type mice (42). Therefore, we applied TimeTeller 203 to an experimental dataset Fang et al. (42) comparing liver samples of REV-ERBα deficient and wild type 204 mice entrained to LD12:12 cycles. Since REV-ERBα is one of the panel of genes used in TimeTeller it 205 would not be surprising that TimeTeller could distinguish REV-ERBα deficient mice from WT mice, and 206 indeed this is the case. Therefore, for this validation, we use a version of TimeTeller that excludes REV-207 ERBα from its panel of genes. This modified TimeTeller clearly detects that the REV-ERBα deficient 208 mice have a functional but significantly perturbed clock when compared to wild-type mice (Fig. 2D) . 209
Although the WT (blue) likelihoods are wide and irregularly shaped, they produce relatively accurate and 210 consistent estimations of ZT around 36h, with corresponding Θs between 0.03 and 0.13 and a mean 211 absolute error of around 2 hours for time estimations of the WT data. This slightly raised estimation error, 212 but good Θ values, could be explained by the discrepancy arising from the use of mice in constant 213 darkness to train TimeTeller to estimate the time of mice that have been in regular LD cycles. The (red) 214 KO likelihoods appear almost entirely flat if not plotted on a logarithmic scale ( Fig. 2C) . 215
Healthy and diseased human tissue have different Θ distributions. 216
Using a leave-one-out approach as above, TimeTeller was used to find the Θ values for the training 217 data, using all ten healthy individuals from Bjarnason et al. This defines the Θ distribution for healthy 218 functioning human clocks and is shown in Fig. 3(A,B) . For most human samples in the training set, Θ < 219 0.09, with a maximum value at Θ = 0.155. The Θ values were relatively uniform across individuals (Fig. 220 S9).This maximum value provides an a priori upper threshold for a "functioning clock" range. When 221 applying TimeTeller to independent human datasets we define a tissue sample to have good clock 222 function (GCF) if Θ < ΘGCF = 0.155. 223
In Fig. 3(A) we also show the Θ distributions for two other healthy datasets which served as 224 controls in the indicated studies, thus emphasizing the similarities in Θ distribution from three 225 independent healthy oral mucosa datasets. The control Θ distributions can then be compared with two 226 cancer datasets that used the same microarray technology, including oral squamous cell carcinoma (41) 227 and breast carcinomas. Similarly, in Fig. 3(B data being significantly biased towards larger values of Θ ( Fig S15) . 252
GCF is associated with a significant survival advantage for breast cancer. 253
Our main application of TimeTeller concerns the REMAGUS multicenter randomised phase II clinical 254 trial which aimed to assess the response of primary breast cancer to different protocols of neoadjuvant 255 chemotherapy according to tumour hormonal receptor status and HER2 expression (37, (46) (47) (48) . Of the 256 trial's 340 patients, 226 had a pretreatment cancer biopsy using the same RNA extraction procedure and 257 analysed with Affymetrix U133A microarrays. There is 10-year survival data for all but two of these. 258
TimeTeller was used to estimate the time and calculate the clock dysfunction metric Θ for all 224 tumour 259 transcriptome samples. 260
To consider whether Θ was indicative of survival we used the threshold above and the 261 definition of Good Clock Function (GCF) and asked whether the survival of those with GCF was 262 different from those without it. A Kaplan-Meier survival analysis (Fig. 4A,B) showed clear statistically 263 significant separation of survival curves with the analysis showing that while 82% of patients with GCF 264 survived for ten years or more, only 61% of the other patients survived as long (p = 0.026) (Fig. 4A) . 265
These results did not depend on this precise choice of threshold but we underline that is chosen a 266 priori using the healthy data and is not chosen by optimising the p-value. 
274
In examining the relation between Θ and survival outcomes we noticed that, if the group without 275 GCF was further subdivided into those with the worst clock function (WCF) (i.e. Θ > ΘWCF = 0.3) and the 276 rest (defined as poor clock function, PCF), we observed an even stronger highly significant survival 277 advantage of GCF over PCF (log rank test p = 0.0058). The threshold ΘWCF for WCF approximately 278 optimised this p-value but the p-value remains well below 0.02 for all choices of the threshold between 279 0.25 and 0.325. We discuss the WCF group below. 280
Dysfunction Θ differs significantly between comparable prognostic factor strata. 281
In the light of these observations, we studied the Θ distributions and hazard ratios for GCF against 282 PCF for each main established prognostic factor stratum. For breast cancer these factors are related to 283 receptors expression above established threshold for estrogen receptors (ER+/ER-); progesterone 284 receptors (PR+/ PR-); and human epidermal growth factor protein receptors (HER2+/HER2-). Prognostic 285 factors also include triple negative (TN) (i.e. ER-, PR-, and HER2-); histologic differentiation grade 286 (well, 1; intermediate, 2 or poor, 3); tumour staging according to size (largest diameter of <5 cm, T1-T2, 287 or > 5 cm, T3-T4); nodal status (pN0/pN1-3); and lympho-vascular invasion (LVI, yes/no). 288
For almost all of the above prognostic factors we find statistically significant differences between 289 the respective strata (Fig. 5 ). High clock dysfunction Θ values characterised breast tumours that were 290 large (T3-4, diameter > 5 cm) rather than small (T1-2) (bilateral t-test, p = 0.014), or were poorly rather 291 than well or moderately well differentiated (Grade 3 vs. 1-2, p = 0.026). Moreover, the clock dysfunction 292 metric had higher values in the breast cancers that did not express estrogen receptors (p = 0.006), and/or 293 progesterone receptors (p = 0.007), or were triple negative (p= 0.0005), as well as in those where 294 neoadjuvant chemotherapy did not achieve pathologic Complete Response (pCR). 
301

Within many strata the calculated hazard ratio reveals a strong survival advantage for GCF 302
We calculated hazard ratios (HRs) of an earlier death for the GCF vs.PCF patients for each factor 303 using the Cox proportional hazards model (49) and performed both univariate (Fig. 6A,B) and 304 multivariate ( Fig. 6C,D,E) analyses. In the univariate analysis we observe a statistically significant 305 survival advantage in terms of the HR for the whole population and for each of the following strata: 306 limited tumour size (T1-T2), a well differentiated tumour (Grade 1 or 2), no lymphovascular invasion 307 (LVI-), ER+, PR-, HER2-, and not displaying high susceptibility to chemotherapy (pCR-) ( Fig. 6B, Fig.  308   S12) . 309
In the multivariate analysis for the whole population and those strata identified by the univariate 310 analysis, the mean HR for both GCF vs. nonGCF and GCF vs. PCF remained well below one implying a 311 strong survival advantage for GCF. For example, in the group of 96 patients with grade 1 or 2 tumours, 312 there is a very advantageous mean HR of 0.24 for GCF vs. PCF with a p-value of 0.021. This means that, 313 holding the other covariates constant, compared to those with PCF there is a 76% reduction in the hazard 314 rate for GCF. We see (Fig. 6D ) that for this group GCF is largely independent of the other factors and has 315 the strongest effect, even stronger than tumour size (a small tumour gives a 60% reduction compared to a 316 large one and other factors have a much smaller effect). Given the modest numbers involved, this is a 317 striking result underlining the strength of GCF and a similar result is found for the even smaller group of 318 tumours that are grade 1 or 2 and HER2 negative. Although, statistical significance at the p < 0.05 level 319 was only found in these strata, a power analysis suggested that all of those identified by the univariate 320 analysis might become significant if the patient group is increased to a few times the current size ( Fig.  321   6F) . Taken together, all the analyses suggest that the circadian clock function of tumours, measured by 322 our metric Θ, adds further independent information and represents itself a potentially useful prognostic 323 and predictive biomarker. The results for GCF vs. notGCF are similar (Fig. S12. & S13) . 
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Does WCF lead to heightened susceptibility to chemotherapy? 355
A Kaplan-Meier survival analysis of GCF vs. PCF vs. WCF (Fig. 4B) shows that the WCF group 356 appear to have a survival advantage up to about 7 or 8 years, but this is not statistically significant with 357 the small group size involved. Given this and the fact that it has previously been observed that severe 358 circadian clock disruption, as caused by Cry1/Cry 2 double knock out, improved the efficacy of 359 chemotherapy (50), we asked whether large values of the dysfunction metric might serve as a predictor 360 for tumor sensitivity to chemotherapy. While the mean clock dysfunction metric showed an increase with 361 grade and stage, we observed higher average Θ values (p = 0.0106; Fig. 5G ) for tumours that best 362 responded to neoadjuvant chemotherapy as indicated by reaching pathological complete response (pCR) 363 which is defined as absence of residual invasive cancer cells in the breast and axillary lymph nodes (grade 364 1 and 2 of Chevallier's classification). Moreover, the rate of pCR was 35% among the WCF patients, as 365 compared to 12% and 13.8% respectively for those cases with GCF and PCF (p < 0.015). In view of these 366 observations, we hypothesise that the initial prolonged survival in the WCF subset is due to their 367 heightened susceptibility to chemotherapy. 368
Discussion 369
Our study had two aims. Firstly, to provide a way of assessing from a single biological sample how 370 well the circadian clock is working, and secondly, to highlight its relevance for circadian medicine 371 through a stringent test. We applied TimeTeller to breast cancer and show that survival and clock 372 functionality were linked. 373
Assessing clock dysfunction. 374
TimeTeller produces an estimate Θ of clock functionality that is based on the likelihood curve 375 LX(t). The key to why this works so well is the correlation structure in the data points at a given time. The 376 G clock genes in our training data are far from independent and although they are noisy and subject to 377 measurement error, they have a clear correlation structure and their covariance matrix has rapidly 378 decreasing eigenvalues. This means that, considered as a vector, they can have an accuracy in assessing 379 time T that is much greater than any single gene. Thus our multi-dimensional approach studying the data 380 in G-dimensional space and combining several dimension-reducing projections is crucial. 381
In our discussion here we have restricted attention to the circadian clock but there is no reason in 382 principle why this approach cannot be applied much more generally. For example, it would be of great 383 interest to apply it to a coupled system such as that involving the circadian clock and cell cycle or to the 384 clock and any representative set of rhythmic downstream genes. Indeed, it is worth noting that one of the 385 genes identified in the mouse model is the gene Wee1 which provides a key connection between the clock 386 and cell cycle (51). 387
Further work is needed to try and understand what aspects of the cells and tissues give rise to the 388 high Θ values we observe in diseased tissue. Since our metric Θ gives a stratification of clock function in 389 cells and tissue we have a way of stratifying cells and using this for a more targeted search to uncover the 390 links between the clock and the mechanisms leading to disease and cellular dysfunction. 391
Breast cancer survival. 392
We have shown a very clear link between Θ and 10-year breast cancer survival in the REMAGUS 393 trial. Despite the large body of work showing that circadian disruption was associated with poor 394 prognosis and that chemotherapy timing could make the difference between life or death in preclinical 395 breast cancer (17) (18) (19) 52) , there was previously no simple method which would allow its measurement in 396 daily oncology practice. Our work has the potential to change this as the method we present only requires 397 a single sample and can be adapted to any gene expression technology. We envisage the use of this metric 398 in conjunction with current prognostic factors to refine treatment management. The results should also 399 open up new opportunities for research into the circadian clock as a target for treatment using the 400 stratification by the dysfunction metric. The techniques developed here can potentially be applied to other 401 diseases involving the circadian clock and other regulatory systems by extending the gene panel outside 402 of the circadian clock in the way discussed above. 403
About 85% of the patients we have studied have tumour samples that were either in the GCF or 404 PCF strata and we saw that for these, disruption of the tumour circadian clock as indicated by PCF is 405 associated with poor survival, suggesting that those patients might benefit from clock-targeted therapies. 406
On the other hand, our work suggested the hypothesis that those patients with WCF samples had 407 heightened susceptibility to chemotherapy. This might suggest that the clinical relevance of the tumour 408 circadian clock function for possible treatment strategies is greatest for those with less agressive tumours. 409 This is also supported by the highly advantageous HRs found in the patients with grade 1 or 2 tumours. 410
However, although tumours that are PR-have a worse prognosis than those that are PR+, it is in the PR-411 stratum that in the univariate analysis GCF provided a very advantageous HR of 0.48 as compared to 412 PCF, whereas there was no apparent advantage to GCF in the PR+ stratum. Overall, we have established 413 a new model for tissue clock functionality and timing determination that could help refine treatment 414 strategies for breast cancer. We expect that the clock model will further display broad implications for 415 circadian medicine at large through enabling the integration of molecular clock determinations in diseased 416 tissues, and the design of innovative clock-targeted therapies with measurable effects. 417
Materials and Methods 418
Analysis of rhythmicity and synchronicity 419
For rhythmicity analysis of the training data we used JTK CYCLE and COSINOR (Fig. S1 , Table  420 S2, Note S3). To measure synchronicity amongst individuals we used an approach using Singular Value 421 Decomposition (SVD) as explained in Note S2. Genes that performed well for both aspects were selected 422 for the TimeTeller mouse and human panels (Fig. S1 , Table S2 ). The number of genes in the panel is 423 denoted by G. 424
For all the work on mouse data, G = 11 and the genes are ARNTL (Bmal1), NPAS2, Clock, 425 NR1D1 (REV-ERBα), NR1D2, PER2, PER3, CIART, DBP, TEF, and WEE1. For the work on human 426 data the analysis identified G = 16 probes from 10 genes ARNTL, NPAS2, PER1, PER2, PER3, NR1D1, 427 NR1D2, CIART, TEF, and DBP. These were used for the leave-one-out analyses but only G =15 of them 428 were used in analysing the independent human datasets. The was because the Per1 probe 244677\_at was 429 found to have significant signal issues in many of the independent datasets, i.e. the signals values were very low. As there is another Per1 probe in this dataset that does not have this problem, we concluded that 431 this is a probe issue, and not an issue with the Per1 gene expression. 432
Construction of the likelihood 433
For each observation j = 1,...,N and each time where i = 1,...,T, the training data for each set of G 434 expression levels is stored in vectors in G-dimensional space. The observations j correspond to 435 tissues for the mouse data and individuals for the human data. Each is then normalised to have a 436 mean of 0 and standard deviation of 1, resulting in the vector . These are the vectors that will be used 437 to parameterise TimeTeller. 438
As each sample is treated individually under both vector normalisation and the initial fRMA 439 normalisation, there is no time-course batch bias in the TimeTeller method. As every vector is 440 independent and the shape information it contains (i.e. the normalised expression levels of the genes) is 441 all that TimeTeller has to go on. However, this also means that the same transcriptome quantification 442 technology for the training and test samples is crucial as illustrated in Fig. S2 . 443
To construct the probability model we firstly construct one for each timepoint by using the local 444 statistical structure of the data at that timepoint and then we combine these. Fix a timepoint . Associated 445 with this is the set of N points in G-dimensional space. The projection operator described in 446 Note S2 gives an optimal way to linearly project these points into d-dimensional space for all d < G. This 447 produces a corresponding set of N d-dimensional points . We then fit a multivariate normal 448 distribution (MVN) to the points . The dimensionality d is chosen so that there are enough vectors 449 to fit a d-dimensional multivariate Gaussian (using the MATLAB function fitgmdist) while ensuring 450 that most of the variance in the data is captured by the d-dimensional projection. In our case we take d = 451 3. A MVN distribution is defined by its mean and covariance matrix which we denote by and 452 respectively. 453 
We fit a shape-preserving smoothing cubic periodic spline through the mean vectors and 464 each of the six entries that determine the 3 3 symmetric matrix so as to extend and 465 to all times t between the time points thus obtaining and . A piecewise cubic Hermite 466 interpolating polynomial spline is used in this case. This type of spline is shape preserving, i.e. continuity 467 of the second derivative is not obligatory. This is suitable as, for example, if two covariance matrix entries 468 were identical for two consecutive time Gaussians, the Hermite spline allows the value of the joining 469 spline to stay the same in the space between, while a standard spline would enforce some change. This 470 spline also interpolates so that it passes through all points. The calculations were carried out using the 471 MATLAB function pchip. Using this approach, for this value of i, we have determined a family of MVN 472 distributions for all times t between the first and last data times. 473
Now we define the likelihood curve
where X is a G-dimensional normalised expression 474 vector using the same genes as the TimeTeller panel. This is given by firstly defining the likelihood 475 associated with the ith timepoint using the probability given by the MVN i.e. 476 477 and then combining them as follows 478
. 479 In Fig. S3 we explain why we use this local approach, using projections calculated locally and then 480 combining them, rather than using a single projection of all the training data. 481
Construction of the clock dysfunction metric Θ 482
We characterise precision using ideas from statistics and information theory. If T is the time at 483 which is maximal (Fig. 1C,D) , and we wish to consider the hypothesis that the time t of the sample 484 is different from T then the Neyman-Pearson lemma tells us how to proceed. According to it, for a given 485 significance level (i.e. probability of a false positive), the most powerful test uses the size of the 486 likelihood ratio and is a test of the form where is chosen so as to obtain a 487 given false-positive error rate. We choose a value of and then define the clock dysfunction metric Θ to 488 be the relative fraction of the times t for which once we have chosen . If Θ is small then 489 determines the time T with high certainty and we interpret this as the clock working well, but if it is large 490 then does not determine the time well and we interpret this as showing a dysfunctional clock. 491
However, the following considerations lead us to use a slightly more complicated approach. We 492 explain in Fig. S4 that the likelihood often has two peaks with another high peak roughly 12 hours 493 away from the MLE. This is because of the elliptic form of our probability distribution in G-dimensional 494 (Fig. S4 ). In this case we would want the metric to penalise the lesser peak, but if the two peaks are 495 close then we would not want this penalty because that is compatible with reasonably good clock function 496 (see Fig. S6 ). As it stands, the metric would not distinguish between these two cases. 497
In view of this, rather than using a constant threshold we use one that is a function of time t, 498 namely, we multiply by where . This is a simple cosine 499 curve transformed so that , and . We define so 500 that C > 0. The larger is, the less anti-phase peaks impact the final confidence metric. The values of 501 and used are explained in the Note S4. 502
The clock dysfunction metric Θ is defined to be the proportion of times t which satisfy 503
504 Some examples of likelihoods and how we would want them to be classified are shown in Fig. S6 . 505
Finally, we note that the above definition does not use the value of the likelihood at its maximum. 506
To ensure that the maximum value achieved is not too small and that exceptionally small values are 507 discounted, we set a minimum value for the likelihoods and we reset to whenever 508 . The parameter reflects the perceived signal-to-noise ratio. It means that the value of the 509 likelihood curve at the MLE must be far greater than this limit for it to be significant, i.e.
. A 510 typical value used for is and this value was chosen manually, by observation of the log-511 likelihood curves. 512 518 Toxicol. 47, 593-628 (2007 
